

groups OH, NH<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> alkanoyl, C<sub>1</sub>-C<sub>4</sub> alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR<sub>3</sub>R<sub>4</sub>, where R<sub>3</sub> and R<sub>4</sub> have the above meanings,

R<sub>2</sub> is hydrogen, halogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) R=R<sub>1</sub>=CH<sub>3</sub>O or OH, R<sub>2</sub>=H,

(b) R=F, R<sub>1</sub>=CH<sub>3</sub>O or OH, R<sub>2</sub>=H, (c) R<sub>1</sub>=-OCH<sub>3</sub>, R=CH<sub>3</sub> and R<sub>2</sub>=H or (d)

R=R<sub>1</sub>=R<sub>2</sub>=CH<sub>3</sub>O,

and X<sup>-</sup> is the monovalent anion of a pharmacologically acceptable acid.

*b) under*  
Cancel claims 12-20 as directed to non-elected subject matter.

#### REMARKS

Reconsideration of this application is requested. Claims 8 to 11 are active in the application subsequent to entry of this amendment.

The Official Action holds claims 12-20 as directed to non-elected subject matter and these claims are now removed to advance prosecution. This action is taken without prejudice to filing a divisional application directed to this subject matter.

An amended title is proposed to agree with the subject matter of the claims now under review.


Claim 10 is allowed and claims 8, 9 and 11 objected to on the basis of prior art. Claim 8 is amended above to exclude the compound of Chem. Abstract 110101 where R=R<sub>1</sub>=R<sub>2</sub>=CH<sub>3</sub>O. For the examiner's information, the copy of this abstract furnished in the International Search Report (copy attached) did not include the compound in question.

Applicants submit claims 8, 9 and 11 are now in condition for allowance. If any issues remain the examiner is requested to contact the undersigned by telephone.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

**NIXON & VANDERHYE P.C.**


By: 

Arthur R. Crawford  
Reg. No. 25,327


ARC:lsp  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

8. (Amended) A 2-aminoteraline of the formula (I)



or a pharmacologically acceptable salt of the formula (II)



wherein:

R and R<sub>1</sub> are independently halogen, hydroxy, or C<sub>1</sub>-C<sub>4</sub> alkoxy optionally substituted in position  $\omega$  with a group selected from OH, NH<sub>2</sub> or NR<sub>3</sub>R<sub>4</sub>, wherein R<sub>3</sub> and R<sub>4</sub> are independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted or substituted in position  $\omega$  with

groups OH, NH<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> alkanoyl, C<sub>1</sub>-C<sub>4</sub> alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR<sub>3</sub>R<sub>4</sub>, where R<sub>3</sub> and R<sub>4</sub> have the above meanings,

R<sub>2</sub> is hydrogen, halogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) R=R<sub>1</sub>=CH<sub>3</sub>O or OH, R<sub>2</sub>=H,

(b) R=F, R<sub>1</sub>=CH<sub>3</sub>O or OH, R<sub>2</sub>=H,[ or] (c) R<sub>1</sub>=-OCH<sub>3</sub>, R=CH<sub>3</sub> and R<sub>2</sub>=H or (d)

R=R<sub>1</sub>=R<sub>2</sub>=CH<sub>3</sub>O,

and X<sup>-</sup> is the monovalent anion of a pharmacologically acceptable acid.